Epidemiology of NAFLD in China Jian-Gao Fan MD, PhD.

Similar documents
At Least 1 in 5 Patients in Your Practice Have Fatty Liver

Non-Alcoholic Fatty Liver Diseasean underestimated epidemic

Nonalcoholic Fatty Liver Disease in Children: Typical and Atypical

NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) NON-ALCOHOLIC STEATOHEPATITIS (NASH) ADDRESSING A GROWING SILENT EPIDEMIC

Non-Alcoholic Fatty Liver Disease

NAFLD/NASH. Definitions. Pathology NASH. Vicki Shah PA-C, MMS Rush University Hepatology

Improving Access to Quality Medical Care Webinar Series

NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) NON-ALCOHOLIC STEATOHEPATITIS (NASH) ADDRESSING A GROWING SILENT EPIDEMIC

La sindrome metabolica e il suo impatto dopo la guarigione nel paziente HIV/HCV

AASLD Immune tolerant phase HBV NAFLD diagnostic HCC

UMHS-PUHSC JOINT INSTITUTE

PEDIATRIC FOIE GRAS: NON-ALCOHOLIC FATTY LIVER DISEASE

Screening for HCCwho,

Transient elastography in chronic liver diseases of other etiologies

Downloaded from zjrms.ir at 3: on Monday February 25th 2019 NAFLD BMI. Kg/m2 NAFLD

What to do about the high ALT picked up at the annual review. Dr Michael Yee Consultant in Diabetes and Endocrinology

Does Viral Cure Prevent HCC Development

NAFLD: evidence-based management. Curso de residentes AEEH Salvador Augustin, MD Liver Unit Vall d Hebron Hospital Barcelona, Spain

NAFLD & NASH: Russian perspective

Jose D Sollano, MD Professor of Medicine University of Santo Tomas Manila, Philippines. University of Santo Tomas

Normal ALT for men 30 IU/L 36% US males abnormal. Abnl ALT. Assess alcohol use/meds. Recheck in 6-8 weeks. still pos

The place of bariatric surgery in NASH: can we extend the indications? - No

PREVALENCE OF NAFLD & NASH

Update on Non-Alcoholic Fatty Liver Disease. Timothy R. Morgan, MD Chief, Hepatology, VA Long Beach Professor of Medicine, UCI

Prognosis of NASH VII Workshop Intenracional de Actualizaçao em Hepatologia, Aug 29th 2014

Treatment as a form of liver cancer prevention The clinical efficacy and cost effectiveness of treatment across Asia

Guidelines for the diagnosis and management of nonalcoholic fatty liver disease: Update 2010

NONALCOHOLIC FATTY LIVER DISEASE. Non-Alcoholic Fatty Liver Disease (NAFLD) Primary NAFLD. April 13, 2012

American Journal of Oral Medicine and Radiology

Clinical dilemmas in HBeAg-negative CHB

Viral hepatitis and Hepatocellular Carcinoma

Fatty Liver- how important is it? Jeremy F.L. Cobbold MA PhD MRCP Clinical Lecturer in Hepatology Imperial College London

White Nights of Hepatology 2016

The role of non-invasivemethods in evaluating liver fibrosis of patients with non-alcoholic steatohepatitis

Non-alcoholic fatty liver disease (NAFLD) is a

Zhang, Q; Wong, CKH; Kung, K; Chan, JCY; Sy, TWB; Lam, M; Xu, XG; Yang, MF; Yu, Y; Lin, XP; Lam, CLK

NAFLD/NASH in Sub- Saharan Africa

HEP DART 2017, Kona, Hawaii

Treatment of HCC in real life-chinese perspective

Cornerstones of Hepatitis B: Past, Present and Future

End Stage Liver Disease & Disease Specific Indications for Liver Transplant. Susan Kang, RN, MSN, ANP-BC

End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP BC

Natural History of Chronic Hepatitis B

METABOLIC SYNDROME AND HCV: FROM HCV

The Impact of HBV Therapy on Fibrosis and Cirrhosis

Screening cardiac patients for advanced liver disease

Early life determinants of Non-Alcoholic Fatty Liver Disease and NASH DR JULIANA MUIVA-GITOBU KENYA PAEDIATRIC ASSOCIATION CONFERENCE APRIL 2016.

Understanding your FibroScan Results

NASH : Diagnosis and investigation. VII Workshop international, Curitiba, Brazil 29/08/2014

Paris Hepatology Conference PROGNOSIS OF NASH

The Effect of Antiviral Therapy on Liver Fibrosis in CHC. Jidong Jia Beijing Friendship Hospital, Capital Medical University

Association between metabolic syndrome and the development of non-alcoholic fatty liver disease

WORLDWIDE EPIDEMIOLOGY OF NASH

Natural History of HBV Infection

«STEATOSI EPATICA ED EPATOPATIE METABOLICHE» Ester Vanni Division of Gastroenterology University of Turin

NIH Public Access Author Manuscript Am J Med Sci. Author manuscript; available in PMC 2015 January 01.

6 Riunione Monotematica A.I.S.F NASH malattia epatica, oncologica e cardiovascolare

/ FIB4 Index , simple steatosis. FIB4 Index. FIB4 Index. FIB4 Index FIB4 Index. Sterling FIB4 Index. FIB4 Index AST AST ALT

Internal and Emergency Medicine Official Journal of the Italian Society of Internal Medicine. ISSN Volume 8 Number 3

Diseases to Watch. Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic

What is NAFLD?.NASH? Presenter Disclosure Information. Learning Objectives. Case 1: Rob. Questions Pertinent to Rob

In Search of New Biomarkers for Nonalcoholic Fatty Liver Disease

The role of ARFI and APRI in diagnosis of liver fibrosis on patients with common chronic liver diseases

Worldwide Causes of HCC

Bariatric Surgery and Liver Transplantation

Worldwide Causes of HCC

Laboratory analysis of the obese child recommendations and discussion. MacKenzi Hillard May 4, 2011

Metabolic Syndrome and HCC. Jacob George

Non alcoholic fatty liver and Non alcoholic Steatohepatitis. By Dr. Seham Seif

Assessment of Liver Stiffness by Transient Elastography in Diabetics with Fatty Liver A Single Center Cross Sectional observational Study

NASH PROGRESS IN THE LAST DECADE

STOP Hepatocellular Carcinoma

Dietary supplementation in treating non-alcoholic fatty liver disease Dr. Ahmad Saedi Associate Professor School of Nutritional Sciences and

Bio Predictive. FibroTest/FibroSure Scientific Publications. Houot 2015 FibroTest, TE, FIB-4, APRI Meta-analysis

FATTY LIVER DISEASE (NAFLD) (NASH) A GROWING

First European NAFLD-NASH Summit European Parliament, Brussels, May 31 st NAFLD/NASH : an expanding burden on liver health

NAFLD and NASH: The Not-So-New Kids on the Block

PEER REVIEW HISTORY ARTICLE DETAILS VERSION 1 REVIEW

Transient elastography in chronic viral liver diseases

NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND NON- ALCOHOLIC STEATOHEPATITIS (NASH) IN ASIAN-PACIFIC REGION

Hepatitis Alert: Management of Patients With HCV Who Have Achieved SVR

Non-Alcoholic Fatty Liver Disease and Metabolic Syndrome in Type 2 Diabetes Mellitus Patients in Rajshahi Medical College Hospital

Why to biopsy? Indications for liver biopsy in common medical liver diseases- how are they changing?

Alimentary Pharmacology and Therapeutics SUMMARY. Background Metabolic syndrome is a known risk factor of cirrhosis in chronic hepatitis B (CHB).

Management of Chronic Hepatitis B in Asian Americans

Currently status of HBV therapy: efficacy and limitations

tage Percent Total & over Total & over Men Women Men Women

NIH Consensus Conference Statement. Management of Hepatitis C. March 24-26, NIH Web site. Available at:

Association of serum adipose triglyceride lipase levels with obesity and diabetes

NAFLD: US GUIDELINES. US Guidelines for NAFLD

HCC Prevention. Jee-Fu Huang. Kaohsiung Municipal Hsiao-Kang Hospital, KMUH Kaohsiung (Takao), Taiwan. TCC, HCC Prevention, 26 Nov, 2011

The Metabolic Syndrome Update The Metabolic Syndrome Update. Global Cardiometabolic Risk

Patient Information Leaflet Non-Alcoholic Fatty Liver Disease (NAFLD) fatty-liver

Disclaimer. Presenter Release are for reactive use by Medical Information only internal learning/educational use only

Chronic Hepatitis B Infection

How to manage patients with NASH? Dr Raluca Pais Institute of Cardiometabolisme and Nutrition (ICAN) Hôpital Pitie Salpetrière, Paris

Don t interfere My first choice is always nucs!

Diabetes Liver Screen

Identifying patients with chronic hepatitis B at high risk of type 2 diabetes mellitus: a cross-sectional study with pair-matched controls

Investigating general liver disease/transaminitis

Transcription:

Epidemiology of NAFLD in China Jian-Gao Fan MD, PhD. Professor and Director Department of Gastroenterology Xinhua Hospital Shanghai Jiaotong University School of Medicine Shanghai 200092, China

Epidemiological studies in FLD Case definition Liver biopsy CT scan Ultrasound FibroScan/FibroTouch FLI, HSI Sampling frame Population Community Clinical based Hospital based --Consecutive/Non-consecutive

Ultrasound of fatty liver

Fatty liver in given specific Chinese population Labor workers in Daqing, Liaonin (n=4100): 5% Labor workers in Beijing (n=1050): 11% Employees in Shaoxing, Zhejiang (n=11372): 10% White collars in Beijing (n=818): 18% White collars in Shanghai (n=4009): 13% Among 6553 employees in Lianyungang, Jiangsu: retired cadre 10%, policemen 9%, clerk 6%, workmen 4% Fan JG. Review. Shijie Huaren Xiaohua Zazhi 2001;9:6-10.

Increased prevalence of fatty liver in China City Period Subjects Trend *Beijing 1998-2003 Administrative officers 23% to 26% Shanghai 1995-2002 Factory workers 4% to 14% Wuhan 1995-2004 Office workers 12.5% to 24.5% Fan JG, JGH 2007;22:663-8. Wang Z. Postgrad Med J 2007;83:192-5. * unpublished

Increased prevalence of FL in Shanghai factory workers between 1995 and 2002 60% 50% 40% 30% 20% 10% 0% 1995-1997- 1999-2001- Fatty liver Habitual drinking FL/Abnormal ALT Obesity Daibetes Hypertension Hyper-TG Hyper-TC Fan JG, et al. J Gastroenterol Hepatol 2007;22:663-68.

Consensus of management of FLD by Chinese Society of Medicine 1 2 3 Guideline for the diagnosis of NAFLD and ALD. Chin J Hepatol 2001 & 2003 Guidelines for diagnosis and treatment of NAFLD & ALD. J Dig Dis 2008; 9:108-116. Chinese Guidelines for diagnosis and management of NAFLD & ALD: update 2010. J Dig Dis 2011; 12: 38-50. 40

Definition of NAFLD There is evidence of hepatic steatosis, either by imaging or by histology, and no causes for secondary steatosis. NAFLD is a highly prevalent form of FLD caused by over-nutrition. NAFLD is an acquired metabolic stressinduced liver diseases associated with insulin resistance and genetic susceptibility.

Fatty liver in general population in China City/Year Prevalence Etiology Others Shanghai/2005 17.3% AFL 0.8%, NAFL 15% Other 1.2% Guangzhou/2007 14.5% AFL 0.5%, NAFL 11.7% Other 1.8% Drinking 13% Children 1.3% Xi an/2008 13.6% AFL 8.7% (?), NAFL 14.7% Drinking 66% Chengdu/2009 12.5% AFL 2.6%, NAFL 6.3% Other 3.6% Beijing/2013 35.1% AFL 4.1%, NAFL 31.3% Shanghai/2014 3721/8810 (40-70 yrs in Chongming Island) NAFLD 42.2% 27.6% in NGT, 45.7% in pre-diabetes, 62.5% in diabetes persons Fan, J Hepatol 2005; 43:508-14. Zhou, WJG 2007;13:6419-24. Yan, Hepatol Int 2008; 2:S86-S87. Li, HBPD Int. 2009;8:377-82.Yan, JGH; 2013, 28:1654-9. Yang Z, Sci Rep. 2016;6:37886.

Prevalence of Fatty Liver in Shanghai Adults Total 17% Male 19% Female 15% 5% 7% AFL Mixed FL NAFLD 15% AFL 0.8% Mixed FL 1.2% NAFLD 88% Fan JG, et al. J Hepatol 2005; 43:508 514

Criteria for obesity and MetS Only 2-3% of Asians classified as obesity by Western criteria. ethnic differences All Asian populations studied had a higher BF% at a lower BMI compared to Caucasians For the same BF%, their BMI was 3-5 units lower compared to Caucasians.

Modified definition for Asians Three or more of the following: Central obesity and/or obesity: Waistline >90 cm (M), >80 cm (F) and/or BMI > 25 kg/m 2 Hypertriglyceridaemia: TG 1.7 mmol/l Low HDL-C: <1.03 mmol/l (M), <1.29 mmol/l (F) High blood pressure: 130/85 mmhg. High fasting glucose: FPG 6.1 mmol/l. Fan JG & Pen YD. HBPT Int 2007

Fan JG, World J Gastroenterol, 2008; 14:2418-24.

Prevalence of NAFLD/NASH in Shanghai 40 35 30 25 20 15 10 5 0 Prevalence of fatty liver and the metabolic syndrome(%) 16-20- 30-40- 50-60- 70 Fatty liver Metabolic syndrome Both prevalence of MetS and NAFLD was 15.3% in Shanghai adults in 2003. In NAFLD, prevalence of MetS and abnormal ALT was 52.9% and 12.7%, respectively. Prevalence of NASH might be between 1.9% and 4.1% in Shanghai adults. 100 90 80 70 60 50 40 30 20 10 0 1 2 3 4 5 BMI<23 BMI23-24.9 BMI>=25 Fan JG, J Gastroenterol Hepatol 2005 with some data unpublished

Prevalence of Lean NAFLD Lean NAFLD is more common in Asia Prevalence of Lean NAFLD in General Population Proportion of Lean NAFLD over all NAFLD 25 20 15 10 5 0 USA (Younossi 2012) KOREA (Cho HC 2016) KOREA (Kim HJ 2004) INDIA (Das K 2010) China (Fan 2007)

Prevalence of NASH in Shanghai Bao-Steel Company A total of 59131 employees of Shanghai Bao-Steel Company were undergone biannual health check-up. Prevalence of abnormal ALT was 4.6%, without obvious changes between 1995 and 2002. Prevalence of fatty liver in patients with abnormal ALT was increased between from 25.9% to 51.4%. Prevalence of NAFLD among 14646 subjects was 13.1% in 2002, percentage of abnormal ALT among NAFLD patients was 16.4%. Prevalence of NASH might be around 2.2% in health check-up adults in 2002. Fan JG, J Gastroenterol Hepatol 2007 with some data unpublished

Incidence of NAFLD in Shanghai 5,226 non-drinking workers without US-fatty liver at baseline. After 2-year follow-up, 310 pts (6.2%) were found to have NAFLD. Incidence of NAFLD (3 new cases/100 people/ year) is equal to that in Dionysos study. The baseline BMI, serum triglyceride and their subtle gain during follow-up were independent predictors of incident of NAFLD. Fan JG, et al. Hepatol International, 2010

Impact of BMI on incidence and remission of NAFLD 30 25 20 20 15 10 5 0-5 -10-15 -20 < 23 23-25 25-30 > 30 Incidence of FL Changes of BMI with FL Changes of BMI without FL 15 10 5 0-5 -10 < 23 23-25 25-30 > 30 Remission rate of FL Changes of BMI with FL remission Changes of BMI persistent with FL 13.6% (60/440) NAFLD was recovery at the end of 2-year follow-up. Zhou C Fan JG. Chin J Intern Med 2012. Chin J Hepatol 2010

Increased prevalence of obesity in Asia 8% 7% 6% 5% 4% 3% 2% China Japan Korea India Indonesia 1% 0% 2000 2005 2010 2014 Year Fan JG, et al. J Hepatol 2017

Global prevalence of NAFLD Younossi Z, et al. Gastroenterology.2016;150:1778-85.

Wang FS, Fan JG, et al. Hepatology 2014; 60:2099-2108.

Etiology of fatty liver in liver clinic in Shanghai 6.4% 7.2% 8.3% Non-alcoholic Alcoholic Virus hepatitis Miscellous 100.00% 90.00% 80.00% 70.00% 60.00% 50.00% 40.00% 30.00% Percent of abnormal ALT Percent 78.1% 20.00% 10.00% 0.00% NAFLD AFL HBV with FL DILI-FL Percent of NASH might be 20% in out-patients with NAFLD. Fan JG, et al. Shanghai Med J, 1998;21:68-70

Liver biopsy from 11 year old male with abnormal LFTs

Histological changes in 152 Chinese pts with NAFLD 100% 0 1 2 3 4 80% 60% 40% 20% 0% steatosis(1/2/3) ballonning degeneration (y/n) NAS(1-3;3-4;5) fibrosis(0-4) Male 73.8%, Age :37±10 yrs, BMI: 26±3 kg/m 2 Percent of NASH in biopsy-proven NAFLD was 41.4%. Advanced fibrosis was 15.8%, associated with MetS and severe inflammation. Xun YH, Fan JG, et al. J Dig Dis, 2012; 13:588-95.

Histological changes of 101 patients with NAFLD Characteristics NAFLD (n=101) None-NASH (n=15) Borderline NASH (n=32) Definitive NASH (n=54) P Steatosis grade,n (%) <0.001 S1 (5-33%) 32 (31.7) 15 (100) 15 (46.9) 2 (3.7) S2 (34-66%) 45 (44.6) 0 17(53.1) 28(51.9) S3 (>66%) 24 (23.8) 0 0 24(44.4) Fibrosis stage, n (%) <0.001 F0 18 (17.8) 7(46.7) 9(28.1) 2(3.7) F1 44 (43.6) 5(33.3) 21(65.6) 18(33.3) F2 26 (25.7) 1(6.7) 1(3.1) 24(44.4) F3 10 (9.9) 2 (13.3) 1(3.1) 7(13.0) F4 3 (3.0) 0 0 3 (5.6) Percent of NASH and cirrhosis was 54% and 3%, respectively Both were associated with T2DM and MetS. Shen F, Fan JG. Liver Int 2015; 35: 2392-400.

Study profile of NAFLD across the Asia Pacific region the GO ASIA initiative Chan WK,.Fan JG,. Wong VWS. Aliment Pharmacol Ther. 2018; 47:816-825.

Percentage of patients with NASH by country the GO ASIA initiative Chan WK,.Fan JG,. Wong VWS. Aliment Pharmacol Ther. 2018; 47:816-825.

Percentage of patients with advanced fibrosis by country the GO ASIA initiative Chan WK,.Fan JG,. Wong VWS. Aliment Pharmacol Ther. 2018; 47:816-825.

Independent factors discriminating the different histological subgroups the GO ASIA initiative Chan WK,.Fan JG,. Wong VWS. Aliment Pharmacol Ther. 2018; 47:816-825.

Natural history of NAFLD according to data from Asia Annual incidence of NAFLD 3-4% 60% can reverse NAFLD by lifestyle intervention 25% progress from NAFL to NASH and have fibrosis progression in 3 yrs Spontaneous reversal of NASH uncommon without intervention Fibrosis progression 1 stage in 7 yrs in NASH; 1 stage in 14 yrs in NAFL No data on reversal of cirrhosis Normal liver NAFL NASH ± fibrosis Cirrhosis Absence of cirrhosis reported in 30-50% of NAFLD-associated HCC in Asians The absolute risk of HCC in noncirrhotic patients is <0.1% per year HCC 1-4% per year Fan JG, Kim SU, Wong WS. J Hepatol 2017

NAFLD leads to liver cancer: do we have sufficient evidence? Duan XY, Qiao L, Fan JG. Cancer letter 2014

www.chzfg.com 32

80% 70% 60% 50% 40% 30% 20% 10% 0% Obesity Hypertension High TG high TC Diabetes MetS NAFLD n=358 Controls n=788 80% 70% 60% 50% 40% 30% 20% 10% 0% hypertension high TG high TC Diabetes FL with Obesity n=274 FL without Obesity n=84 Obesity alone n=174 Nor FL or obesity n=614 Fan JG, et al. JGH 2007;22:1086-91.

上海宝钢队列糖尿病发病率与危险度比 基线特征 DM 发病数 DM 发病率 (%) 危险度比 (HR) N=12438,follow-up 6 years 95% CI 下限 95% CI 上限 肥胖 BMI <25 kg/m 2 215 4.1 1 - - BMI 25 kg/m 2 155 11.4 2.41 1.95 2.98 IFG (-) 233 3.95 1 - - (+) 147 15.61 3.67 2.97 4.52 高 TG 血症 (-) 197 4.05 1 - - (+) 173 10 2.16 1.75 2.65 高 TC 血症 (-) 311 5.16 1 - - (+) 59 10.46 1.43 1.04 1.95 脂肪肝 (-) 322 5.05 1 - - (+) 48 22.86 4.07 3 5.51 高 Hb 血症 (-) 320 5.32 1 - - (+) 50 8.73 1.25 0.92 1.7 Fan JG, et al. J Diabetes Investig. 2016; 7:206-211.

上海崇明脂肪肝流行病学调查 Circulating periostin in relation to insulin resistance and NAFLD among overweight and obese subjects. Sci Rep. 2016;6:37886. Plasma selenium levels and NAFLD in Chinese adults: a cross-sectional analysis. Sci Rep. 2016; 6:37288. Plasma osteoprotegerin levels are inversely associated with NAFLD in patients with type 2 diabetes: A case-control study in China. Metabolism. 2016; 65(4):475-81. Association of calf circumference with insulin resistance and NAFLD: the REACTION study. BMC Endocr Disord. 2017;17(1):28. Impaired lung function is associated with NAFLD independently of metabolic syndrome features in middle-aged and elderly Chinese. BMC Endocr Disord. 2017; 17(1):18.

Fatty liver & HBV infection in Chinese Inverse association between HBsAg+ve and ultrasound-diagnosed fatty liver both in Shanghai and Taipei. Fan JG, et al. World J Gastroenterol 2003. Cheng YL, et al. Plos One 2013 Inverse association between HBV infection and MRS-diagnosed fatty liver in Hong Kong adults. Wong VWS, et al. J Hepatol 2012 Inverse association between HBV infection and hypertriglyceridemia and MetS. Luo et al. Clin Chim Acta. 2007; Jan et al. Int J Obes 2006; Wong et al. J Hepatol 2012

Ye DW, Fan JG, et al.aasld,2009

Fan JG, et al. AASLD 2016

Fatty liver & CHB in Our Group 1 Hepatitis B and fatty liver: causal or coincidental? J Gastroenterol Hepatol. 2008; 23(5):679-81. 2 3 4 5 6 7 8 9 10 Prevalence and risk factors of hepatic steatosis and its impact on liver injury in Chinese patients with CHB infection. J Gastroenterol Hepatol. 2008; 23:1419-25. Fatty liver reduces hepatitis B virus replication in a genotype B hepatitis B virus transgenic mice model. J Gastroenterol Hepatol. 2012; 27:1858-64. Hepatic Steatosis Is Highly Prevalent in CHB Patients and Negatively Associated with Virological Factors. Dig Dis Sci. 2014; 59:2571-9. Saturated fatty acid Inhibits Viral Replication in HBV Infection with NAFLD by TLR4 Mediated Innate Immune Response. Hepat Mon. 2015; 15:e27909. CAP for noninvasive assessment of hepatic steatosis using Fibroscan: Validation in chronic hepatitis B. Dig Dis Sci 2015; 60:243-51. Thyroid function is associated with NAFLD in chronic hepatitis B infected subjects. J Gastroenterol Hepatol. 2015; 30:1753-1758. Linked polymorphisms of PNPLA3 confer susceptibility to NASH and decreased viral load in chronic hepatitis B. World J Gastroenterol. 2015; 21:8605-8614. PNPLA3 rs1010023 predisposes CHB to hepatic steatosis, but improves insulin resistance and glucose metabolism. J Diabetes Res. 2017; 2017:4740124. Serum Monounsaturated Triacylglycerol Predicts Steatohepatitis in Patients with NAFLD and CHB. Sci Rep. 2017, 7:10517.

What are the settings for NAFLD? Overweight/Central obesity 50% Steatosis 10%-40% Steatohepatitis 50% Liver fibrosis 15%~30% Cirrhosis & HCC 30%~40% MetS T2DM Cancer & CVD Liver-related mortality Patrick L. Altern Med Rev, 2002, 7:276-291 Fan JG. JGH, 2007;22:794-800. JDD 2008;9:63-70

NAFLD is not just a Western problem Prevalence of fatty liver increased rapidly in past decades with obesity and MetS pandemic in China. Fatty liver is more often associated with obesity than with alcoholism. Chronic HBV infection do not account for increased trend of fatty liver and fatty liver increased in CHB as well. Cardiovascular and diabetic risk may compete with liver disease-related risk in dictating the final outcome. NAFLD is emerging into a new and major health problem in Chinese. Fan JG. J Hepatol 2009; JGH 2013.

Thanks for for your attention!